Skip to content

QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.

Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01223534
Acronym
OPTIMIST
Enrollment
871
Registered
2010-10-19
Start date
2010-07-31
Completion date
2016-02-29
Last updated
2016-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Latent Tuberculosis Infection

Keywords

Tuberculosis, Latent tuberculosis infection, Tuberculin skin test, Interferon-gamma release assays, Contact-tracing study

Brief summary

Hypothesis: a combined strategy of tuberculin skin test (TST) followed by QuantiFERON-TB Gold In-Tube (QFT-IT) to confirm positivity (tuberculosis infection,in contact-tracing study will allow avoiding unnecessary preventive treatment without increasing rates of tuberculosis cases among contacts screened. Aim of the study: to compare a combined strategy of the TST and the QFT-IT with TST alone for the diagnosis of tuberculosis infection and for therapeutic decision in contact tracing study. Design and setting: Prospective, multicentre, comparative study in 12 hospitals in Spain. Study population: 870 subjects, household contacts of patients with culture positive pulmonary and/or laryngeal tuberculosis will be randomized to one of two strategies: Arm A (standard practice), in which treatment decisions will be based on the TST result, and Arm B (experimental), in which treatment decisions will be based on the QFT result. Interventions: participants in arm A will undergo TST; participants in arm B will undergo TST, and, in case of a positive result, QFT-IT as well. Participants with positive TST (arm A) and positive QFT-IT (arm B) will be diagnosed with tuberculosis infection and will be treated with isoniazid for 6 months. All participants will be followed for two years. End-points of evaluation: development of tuberculosis and proportion of subjects for whom treatment is prescribed in each arm.

Interventions

DRUGPreventive treatment with Isoniazid.

If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.

DRUGPreventive treatment with Isoniazid

If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.

Sponsors

Cellestis
CollaboratorINDUSTRY
Hospital Universitari de Bellvitge
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years. * Close contact of a pulmonary and/or laryngeal tuberculosis case. * Written informed consent.

Exclusion criteria

* HIV infection. * Immunosuppression other than HIV, such as decompensated liver disease, chronic renal failure, corticosteroids treatment, malignancy under chemotherapy therapy. * Prior tuberculosis or positive TST. * Strain resistant to Isoniazid (index case).

Design outcomes

Primary

MeasureTime frame
Development of tuberculosis.Assessment of primary end-point: 24 months after randomization.

Secondary

MeasureTime frame
Prescription of treatment.The day 0 (visit 2) after randomization.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026